Top

Published in:

Open Access 01-12-2024 | Migraine | Research

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

Authors: Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, Mattia Canella, Marilena Marcosano, Claudia Altamura, Fabrizio Vernieri

Published in: The Journal of Headache and Pain | Issue 1/2024

Abstract

Background

Chronic migraine (CM) is a disabling condition with high prevalence in the general population. Until the recent approval of monoclonal antibodies targeting the calcitonin gene-related peptide (Anti-CGRP mAbs), OnabotulinumtoxinA (BoNT-A) was the only treatment specifically approved for CM prophylaxis. Direct comparisons between the two treatments are not available so far.

Methods

We performed an observational, retrospective, multicenter study in Italy to compare the real-world effectiveness of Anti-CGRP mAbs and BoNT-A. Patients with CM who had received either treatment according to Italian prescribing regulations were extracted from available clinical databases. Efficacy outcomes included the change from baseline in monthly headache days (MHD), MIgraine Disability ASsessment test (MIDAS), and monthly acute medications (MAM) evaluated at 6 and 12 months of follow-up. The primary outcome was MHD change from baseline at 12 months. Safety outcomes included serious adverse events (SAE) and treatment discontinuation. Unadjusted and adjusted models were used for the analyses.

Results

Two hundred sixteen potentially eligible patients were screened; 183 (86 Anti-CGRP mAbs; 97 BoNT-A) were included. One hundred seventy-one (80 Anti-CGRP mAbs; 91 BoNT-A) and 154 (69 Anti-CGRP mAbs; 85 BoNT-A) patients were included in the efficacy analysis at 6 and 12 months of follow-up, respectively. Anti-CGRP mAbs and BoNT-A both resulted in a mean MHD reduction at 6 (-11.5 and -7.2 days, respectively; unadjusted mean difference -4.3; 95%CI -6.6 to -2.0; p = 0.0003) and 12 months (-11.9 and -7.6, respectively; unadjusted mean difference -4.4; 95%CI -6.8 to -2.0; p = 0.0002) of follow-up. Similar results were observed after adjusting for baseline confounders. Anti-CGRP mAbs showed a significant MIDAS (-31.7 and -19.2 points, p = 0.0001 and p = 0.0296, respectively) and MAM reduction (-5.1 and -3.1 administrations, p = 0.0023 and p = 0.0574, respectively) compared to BoNT-A at 6 and 12 months. No SAEs were reported. One patient receiving fremanezumab discontinued treatment due to arthralgia. Treatment discontinuations, mainly for inefficacy, were comparable.

Conclusion

Both Anti-CGRP mAbs and BoNT-A were effective in CM patients with Anti-CGRP mAbs presenting higher effect magnitude, with comparable safety. Still, BoNT-A remains a valuable option for CM patients with contraindications to Anti-CGRP mAbs or for frail categories who are candidates to local therapy with limited risk of systemic administration.

Graphical Abstract

Available only for authorised users

Natoli JL, Manack A, Dean B et al (2009) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609. https://doi.org/10.1111/j.1468-2982.2009.01941.xCrossRef

Diener H-C, Solbach K, Holle D, Gaul C (2015) Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin Med 15:344–350. https://doi.org/10.7861/clinmedicine.15-4-344CrossRef

Agostoni EC, Barbanti P, Calabresi P et al (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 20:92. https://doi.org/10.1186/s10194-019-1038-4CrossRefPubMedPubMedCentral

Chen Y-Y, Ye X-Q, Tang T-C et al (2021) Calcitonin gene-related peptide monoclonal antibodies Versus Botulinum Neurotoxin a in the Preventive treatment of chronic migraine: an adjusted Indirect Treatment Comparison Meta-Analysis. Front Pharmacol 12:671845. https://doi.org/10.3389/fphar.2021.671845CrossRefPubMedPubMedCentral

Becker WJ (2020) Botulinum Toxin in the Treatment of Headache. Toxins (Basel) 12(12):803. https://doi.org/10.3390/toxinsCrossRefPubMed

Herd CP, Tomlinson CL, Rick C et al (2019) Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open 9:e027953. https://doi.org/10.1136/bmjopen-2018-027953CrossRefPubMedPubMedCentral

Shen B, Wang L (2020) Impact of the botulinum-A toxin on prevention of adult migraine disorders. J Integr Neurosci 19:201–208. https://doi.org/10.31083/j.jin.2020.01.1240CrossRefPubMed

Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803. https://doi.org/10.1177/0333102410364676CrossRefPubMed

Aurora SK, Winner P, Freeman MC et al (2011) OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51:1358–1373. https://doi.org/10.1111/j.1526-4610.2011.01990.xCrossRefPubMed

10.

Lipton RB, Varon SF, Grosberg B et al (2011) OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 77:1465–1472. https://doi.org/10.1212/WNL.0b013e318232ab65CrossRefPubMed

11.

Aurora SK, Dodick DW, Diener H-C et al (2014) OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 129:61–70. https://doi.org/10.1111/ane.12171CrossRefPubMed

12.

Diener H-C, Dodick DW, Turkel CC et al (2014) Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol 21:851–859. https://doi.org/10.1111/ene.12393CrossRefPubMedPubMedCentral

13.

Dodick DW, Turkel CC, DeGryse RE et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936. https://doi.org/10.1111/j.1526-4610.2010.01678.xCrossRefPubMed

14.

Blumenfeld AM, Stark RJ, Freeman MC et al (2018) Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 19:13. https://doi.org/10.1186/s10194-018-0840-8CrossRefPubMedPubMedCentral

15.

Schoenen J, Manise M, Nonis R et al (2020) Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention. Rev Neurol (Paris) 176:788–803. https://doi.org/10.1016/j.neurol.2020.04.027CrossRefPubMed

16.

Raffaelli B, Neeb L, Reuter U (2019) Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 19:1307–1317. https://doi.org/10.1080/14712598.2019.1671350CrossRefPubMed

17.

Dodick DW, Lipton RB, Silberstein S et al (2019) Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 39:1075–1085. https://doi.org/10.1177/0333102419858355CrossRefPubMed

18.

Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the Preventive treatment of chronic migraine. N Engl J Med 377:2113–2122. https://doi.org/10.1056/NEJMoa1709038CrossRefPubMed

19.

McAllister P, Lamerato L, Krasenbaum LJ et al (2021) Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain 22:156. https://doi.org/10.1186/s10194-021-01358-9CrossRefPubMedPubMedCentral

20.

Detke HC, Goadsby PJ, Wang S et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211–e2221. https://doi.org/10.1212/WNL.0000000000006640CrossRefPubMedPubMedCentral

21.

Camporeale A, Kudrow D, Sides R et al (2018) A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol 18:188. https://doi.org/10.1186/s12883-018-1193-2CrossRefPubMedPubMedCentral

22.

Ament M, Day K, Stauffer VL et al (2021) Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. J Headache Pain 22:6. https://doi.org/10.1186/s10194-021-01215-9CrossRefPubMedPubMedCentral

23.

Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94:e1365–e1377. https://doi.org/10.1212/WNL.0000000000009169CrossRefPubMedPubMedCentral

24.

Silberstein S, Diamond M, Hindiyeh NA et al (2020) Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain 21:120. https://doi.org/10.1186/s10194-020-01186-3CrossRefPubMedPubMedCentral

25.

Kudrow D, Cady RK, Allan B et al (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21:126. https://doi.org/10.1186/s12883-021-02123-wCrossRefPubMedPubMedCentral

26.

Lipton RB, Tepper SJ, Reuter U et al (2019) Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology 92:e2250–e2260. https://doi.org/10.1212/WNL.0000000000007452CrossRefPubMedPubMedCentral

27.

Lambru G, Hill B, Murphy M et al (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61. https://doi.org/10.1186/s10194-020-01127-0CrossRefPubMedPubMedCentral

28.

Scheffler A, Messel O, Wurthmann S et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21:84. https://doi.org/10.1186/s10194-020-01151-0CrossRefPubMedPubMedCentral

29.

Bigal ME, Edvinsson L, Rapoport AM et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091–1100. https://doi.org/10.1016/S1474-4422(15)00245-8CrossRefPubMed

30.

Goadsby PJ, Silberstein SD, Yeung PP et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 95:e2487–e2499. https://doi.org/10.1212/WNL.0000000000010600CrossRefPubMedPubMedCentral

31.

Xu D, Chen D, Zhu L-N et al (2019) Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia 39:1164–1179. https://doi.org/10.1177/0333102419829007CrossRefPubMed

32.

Scheffler A, Schenk H, Wurthmann S et al (2021) CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. J Headache Pain 22:111. https://doi.org/10.1186/s10194-021-01323-6CrossRefPubMedPubMedCentral

33.

Torres-Ferrús M, Gallardo VJ, Alpuente A et al (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268:3789–3798. https://doi.org/10.1007/s00415-021-10523-8CrossRefPubMed

34.

Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https://doi.org/10.1186/s10194-018-0955-yCrossRefPubMedPubMedCentral

35.

Sacco S, Amin FM, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain 23:67. https://doi.org/10.1186/s10194-022-01431-xCrossRefPubMedPubMedCentral

36.

Alpuente A, Gallardo VJ, Caronna E et al (2021) Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study. Eur J Neurol 28:2378–2382. https://doi.org/10.1111/ene.14828CrossRefPubMed

37.

Lu J, Zhang Q, Guo X et al (2021) Calcitonin gene-related peptide monoclonal antibody Versus Botulinum Toxin for the Preventive treatment of chronic migraine: evidence from Indirect Treatment comparison. Front Pharmacol 12:631204. https://doi.org/10.3389/fphar.2021.631204CrossRefPubMedPubMedCentral

38.

Stewart WF, Lipton RB, Kolodner KB et al (2000) Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88:41–52. https://doi.org/10.1016/S0304-3959(00)00305-5CrossRefPubMed

39.

Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814CrossRefPubMed

40.

Sakai F, Suzuki N, Kim B-K et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61:1092–1101. https://doi.org/10.1111/head.14169CrossRefPubMedPubMedCentral

41.

Takeshima T, Sakai F, Hirata K et al (2021) Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache 61:927–935. https://doi.org/10.1111/head.14138CrossRefPubMedPubMedCentral

42.

Affatato O, Moulin TC, Pisanu C et al (2021) High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. J Transl Med 19:133. https://doi.org/10.1186/s12967-021-02801-wCrossRefPubMedPubMedCentral

43.

Freitag FG, Diamond S, Diamond M, Urban G (2008) Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache 48:201–209. https://doi.org/10.1111/j.1526-4610.2007.00963.xCrossRefPubMed

44.

Frank F, Ulmer H, Sidoroff V, Broessner G (2021) CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis. Cephalalgia 41:1222–1239. https://doi.org/10.1177/03331024211018137CrossRefPubMedPubMedCentral

45.

Barbanti P, Egeo G, Aurilia C et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23:46. https://doi.org/10.1186/s10194-022-01396-xCrossRefPubMedPubMedCentral

46.

Lattanzi S, Brigo F, Trinka E et al (2019) Erenumab for Preventive Treatment of Migraine: a systematic review and Meta-analysis of efficacy and safety. Drugs 79:417–431. https://doi.org/10.1007/s40265-019-01069-1CrossRefPubMed

47.

Barbanti P, Aurilia C, Cevoli S et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache 61:1351–1363. https://doi.org/10.1111/head.14194CrossRefPubMed

48.

Vernieri F, Brunelli N, Marcosano M et al (2023) Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: the multicenter prospective cohort GARLIT study. Eur J Neurol 30:224–234. https://doi.org/10.1111/ene.15563CrossRefPubMed

49.

Caponnetto V, Russo A, Silvestro M, et al (2023) Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study. CNS Drugs. https://doi.org/10.1007/s40263-023-01050-3

50.

Melo-Carrillo A, Noseda R, Nir R-R et al (2017) Selective inhibition of Trigeminovascular neurons by Fremanezumab: a humanized monoclonal Anti-CGRP antibody. J Neurosci off J Soc Neurosci 37:7149–7163. https://doi.org/10.1523/JNEUROSCI.0576-17.2017CrossRef

51.

Brin MF, Burstein R (2023) Botox (onabotulinumtoxinA) mechanism of action. Med (Baltim) 102:e32372. https://doi.org/10.1097/MD.0000000000032372CrossRef

52.

Pellesi L (2023) Combining onabotulinumtoxin A with a CGRP antagonist for chronic migraine prophylaxis: where do we stand? Front Pain Res 4:1292994CrossRef

53.

Altamura C, Brunelli N, Marcosano M et al (2022) Gepants - a long way to cure: a narrative review. Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol 43:5697–5708. https://doi.org/10.1007/s10072-022-06184-8CrossRef

54.

Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M (2022) OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. Toxins (Basel) 14:847. https://doi.org/10.3390/toxins14120847CrossRefPubMed

55.

Blumenfeld AM, Frishberg BM, Schim JD et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody Therapy added to OnabotulinumtoxinA: a Retrospective Chart Review. Pain Ther 10:809–826. https://doi.org/10.1007/s40122-021-00264-xCrossRefPubMedPubMedCentral

56.

Reuter U, Ehrlich M, Gendolla A et al (2022) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42:108–118. https://doi.org/10.1177/03331024211053571CrossRefPubMed

57.

Forbes RB, McCarron M, Cardwell CR (2020) Efficacy and Contextual (Placebo) effects of CGRP antibodies for migraine: systematic review and Meta-analysis. Headache 60:1542–1557. https://doi.org/10.1111/head.13907CrossRefPubMed

58.

Baraldi C, Lo Castro F, Ornello R et al (2023) OnabotulinumtoxinA: Still the Present for Chronic Migraine. Toxins (Basel) 15(1):59CrossRefPubMedPubMedCentral

59.

Hepp Z, Rosen NL, Gillard PG et al (2016) Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: retrospective analysis of a US-based insurance claims database. Cephalalgia 36:862–874. https://doi.org/10.1177/0333102415621294CrossRefPubMed

60.

Rothrock J (2020) Treatment with Onabotulinumtoxin A versus Erenumab for patients with Acquired/Post-traumatic chronic migraine. Eur J Neurol 27:305

61.

Siersbæk N, Kilsdal L, Jervelund C et al (2023) Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC Neurol 23:254. https://doi.org/10.1186/s12883-023-03302-7CrossRefPubMedPubMedCentral

62.

Altamura C, Ornello R, Ahmed F et al (2023) OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study. J Neurol 270:986–994. https://doi.org/10.1007/s00415-022-11457-5CrossRefPubMed

63.

Wong H-T, Khalil M, Ahmed F (2020) OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. J Headache Pain 21:129. https://doi.org/10.1186/s10194-020-01196-1CrossRefPubMedPubMedCentral

64.

Altamura C, Brunelli N, Marcosano M et al (2023) Eptinezumab for the Prevention of Migraine: clinical utility, patient preferences and selection – a narrative review. Ther Clin Risk Manag 19:595–971. https://doi.org/10.2147/TCRM.S263824CrossRef

65.

Palacios-Ceña D, Ordás-Bandera C, Casas-Limón J et al (2023) Real-world experience of OnabotulinumtoxinA treatment in female patients with chronic migraine: a qualitative study using in-depth interviews. Ann Med 55:2255215. https://doi.org/10.1080/07853890.2023.2255215CrossRefPubMed

Title: Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
Authors: Licia Grazzi
Riccardo Giossi
Danilo Antonio Montisano
Mattia Canella
Marilena Marcosano
Claudia Altamura
Fabrizio Vernieri
Publication date: 01-12-2024
Publisher: Springer Milan
Keywords: Migraine
Fremanezumab
Erenumab
Galcanezumab
Medication Overuse Headache
Published in: The Journal of Headache and Pain / Issue 1/2024
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-024-01721-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

Abstract

Background

Methods

Results

Conclusion

Graphical Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Microglia TREM1-mediated neuroinflammation contributes to central sensitization via the NF-κB pathway in a chronic migraine model

The burden attributable to primary headache disorders in children and adolescents in Ethiopia: estimates from a national schools-based study

Health-related quality of life, work ability and disability among individuals with persistent post-dural puncture headache

LncRNA Anxa10-203 enhances Mc1r mRNA stability to promote neuropathic pain by recruiting DHX30 in the trigeminal ganglion

Health equity, care access and quality in headache – part 1

Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study